摘要
顺铂是目前在临床上使用的领先的化疗药物之一。然而,它的严重的副作用和其抗肿瘤细胞的发展阻碍了它的使用。为了减少其副作用并保持抗癌效率,各种顺铂为基础的制剂进行了开发。在这篇综述中,我们总结了顺铂传递策略的最新进展,包括直接传递、传递前体药物和组合传递。识别了阻碍改进药物制剂发展的关键性挑战,并总结了有效的方法去解决在这些最近的论文中所提到的问题。
关键词: 顺铂;组合递送;药物递送;耐药性;前药;肿瘤治疗
图形摘要
Current Cancer Drug Targets
Title:Current Strategy for Cisplatin Delivery
Volume: 16 Issue: 6
Author(s): Zhanguo Yue, Zhiqiang Cao
Affiliation:
关键词: 顺铂;组合递送;药物递送;耐药性;前药;肿瘤治疗
摘要: Cisplatin is one of the leading chemotherapy drugs currently used in clinical settings. However, its serious side effects and its resistance developed by tumor cells hinder its usage. To decrease its side effects and maintain anti-cancer efficiency, various cisplatin based formulations were developed. In this minireview, we summarized the recent progress of cisplatin delivery strategies, including direct delivery, prodrug delivery and combination delivery. Key challenges preventing the development of improved drug formulations were identified, and effective approaches to address these issues were discussed in the context of these recent works.
Export Options
About this article
Cite this article as:
Zhanguo Yue, Zhiqiang Cao , Current Strategy for Cisplatin Delivery, Current Cancer Drug Targets 2016; 16 (6) . https://dx.doi.org/10.2174/1568009616666160328113006
DOI https://dx.doi.org/10.2174/1568009616666160328113006 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obesity in China: What are the Causes?
Current Pharmaceutical Design Immunotoxins and Other Conjugates: Pre-clinical Studies
Mini-Reviews in Medicinal Chemistry Synthesis of Some Coumarinyl Chalcones and their Antiproliferative Activity Against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Antibody Fragment and Targeted Colorectal Cancer Therapy: A Global Systematic Review
Current Pharmaceutical Biotechnology Epidermal Cell Proliferation in Calorie-Restricted Aging Rats
Current Aging Science Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Thiomers, Mucoadhesion and Oral Delivery of Biomacromolecules
Current Drug Therapy Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Drug-Eluting Stents: Present and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Identifying Biomarkers of Lung Cancer in the Post-Genomic Era
Current Pharmacogenomics Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Electrochemical Study of DNA Damaged by Oxidation Stress
Combinatorial Chemistry & High Throughput Screening Androgen Pathway Related Gene Variants and Prostate Cancer Association in Auckland Men
Current Pharmacogenomics and Personalized Medicine Multiple Target-Specific Molecular Imaging Agents Detect Liver Cancer in a Preclinical Model
Current Molecular Medicine Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors
Current Pharmaceutical Design Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets